Red blood cell transfusion survival in sickle cell disease is reduced by donor characteristics and recipient spleen activity.

Saved in:
Bibliographic Details
Title: Red blood cell transfusion survival in sickle cell disease is reduced by donor characteristics and recipient spleen activity.
Authors: Yee MEM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA., Zerra PE; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA.; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA., Francis RO; Department of Pathology and Cell Biology, Columbia University Medical Center, New York Presbyterian Hospital, New York, NY., Easley KA; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Atlanta, GA., Lough CM; LifeSouth Community Blood Centers, Gainesville, FL., McCoy JW; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA., Naseh Z; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA., Delvadia BB; Transfusion Services, Northside Hospital, Atlanta, GA., Parikh AK; Department of Radiology, Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA., Butler HE; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA., Stowell SR; Joint Program in Transfusion Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Joiner CH; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA., Josephson CD; Cancer and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, FL.; Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD.; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD., Roback JD; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA., Fasano RM; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA.; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA.
Source: Blood advances [Blood Adv] 2026 Jul 14; Vol. 10 (13), pp. 4439-4449.
Publication Type: Journal Article; Clinical Trial
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025019005